Omapatrilat

DB00886ExperimentalSmall molecule

Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine,... This drug from BMS was not approved by the FDA due to angioedema safety concerns.

Mechanism: Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
Curator reviewed
Primary indication: For the treatment of hypertension.Curator reviewed
Formula / weight: C₁₉H₂₄N₂O₄S₂ · 408.53 g/mol (avg)
Also known as: Omapatrilate
Code names: BMS-186716 · BMS-186716-01

Resolves to

Compound

UNII36NLI90E7TCAS167305-00-2ChEMBLCHEMBL289556ChEBI135660PubChem656629KEGGD01970

Structure

InChIKeyLVRLSYPNFFBYCZ-VGWMRTNUSA-NSMILES[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O

Targets

P08473MMEP12821ACE

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

852Drug interactionsStructured to mechanism, not free text

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Omapatrilat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account